目的研究血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶-26(MMP-26)、基质金属蛋白酶抑制剂-4(TIMP-4)与弥漫大B细胞淋巴瘤(Diffuse large B celllymphoma,DLBCL)病理分期及预后的相关性。方法选取2021年1月1日至2022年4月1日于上海交...目的研究血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶-26(MMP-26)、基质金属蛋白酶抑制剂-4(TIMP-4)与弥漫大B细胞淋巴瘤(Diffuse large B celllymphoma,DLBCL)病理分期及预后的相关性。方法选取2021年1月1日至2022年4月1日于上海交通大学医学院附属瑞金医院治疗的75例DLBCL患者为研究组,另选取75例淋巴结反应性增生患者作为对照组,观察研究组与对照组及研究组不同分期、不同发病部位血清MMP-9、MMP-26及TIMP-4水平;采用Spearman分析DLBCL患者血清MMP-9、MMP-26与TIMP-4间的相关性;绘制Kaplan-Meier生存曲线,分析MMP-9、MMP-26、TIMP-4水平与DLBCL患者预后的关系。结果研究组血清MMP-9、MMP-26水平均高于对照组,血清TIMP-4水平均低于对照组,差异有统计学意义(P<0.05)。研究组Ⅰ~Ⅱ期患者血清MMP-9、MMP-26水平低于Ⅲ~Ⅳ期患者,血清TIMP-4水平高于Ⅲ~Ⅳ期患者,差异有统计学意义(P<0.05)。研究组不同发病部位患者血清MMP-9、MMP-26、TIMP-4水平比较差异均无统计学意义(P>0.05)。DLBCL患者血清MMP-9、MMP-26水平与TIMP-4水平呈负相关(P<0.05);血清MMP-9水平与MMP-26水平正相关(P<0.05)。MMP-9和MMP-26高表达、TIMP-4低表达组患者累积生存率低于其他组患者,差异具有统计学意义(P<0.05)。结论血清MMP-9、MMP-26及TIMP-4水平与DLBCL病理分期及患者预后密切相关,检测血清MMP-9、MMP-26及TIMP-4水平有助于明确DLBCL病理分期及评价患者预后。展开更多
Prostate cancer is one of the leading health threats to man,and like many other cancers,early detection and treatment iscrucial to improving the prognosis of patients.Progression of the disease from noninvasive high-g...Prostate cancer is one of the leading health threats to man,and like many other cancers,early detection and treatment iscrucial to improving the prognosis of patients.Progression of the disease from noninvasive high-grade prostatic intraepi-thelial neoplasia (HGPIN) to invasive adenocarcinoma is linked to the action of a group of proteolytic enzymes calledmatrix metalloproteinases (MMPs),which digest various components of the extracellular matrix and thus open waysfor tumor metastasis.Previous studies have shown that one MMP,MMP-26,is expressed at a significantly higher levelin human prostate carcinoma than in normal prostate tissues,and that it appears to play an important role in promotinginvasion of prostate cancer cells [1].In this issue of Cell Research,Lee et al.report detailed analyses of the expressionpattern of MMP-26,along with its most potent endogenous inhibitor,TIMP-4 (TIMP stands for tissue inhibitor ofmetal-loproteinases),in a number of prostate cancer samples derived from human patients [2].Interestingly,they found展开更多
The identification of novel biomarkers for early prostate cancer diagnosis is highly important because early detection and treatment are critical for the medical management of patients. Disruption in the continuity of...The identification of novel biomarkers for early prostate cancer diagnosis is highly important because early detection and treatment are critical for the medical management of patients. Disruption in the continuity of both the basal cell layer and basement membrane is essential for the progression of high-grade prostatic intraepithelial neoplasia （HGPIN） to invasive adenocarcinoma in human prostate. The molecules involved in the conversion to an invasive phenotype are the subject of intense scrutiny. We have previously reported that matrix metalloproteinase-26 （MMP-26） promotes the invasion of human prostate cancer cells via the cleavage of basement membrane proteins and by activating the zymogen form of MMP-9. Furthermore, we have found that tissue inhibitor of metalloproteinases-4 （TIMP-4） is the most potent endogenous inhibitor of MMP-26. Here we demonstrate higher （p〈0.0001） MMP-26 and TIMP-4 expression in HGPIN and cancer, compared to non-neoplastic acini. Their expression levels are highest in HGPIN, but decline in invasive cancer （p〈0.001 for each） in the same tissues. Immunohistochemical staining of serial prostate cancer tissue sections suggests colocalization of MMP-26 and TIMP-4. The present study indicates that MMP-26 and TIMP-4 may play an integral role during the conversion of HGPIN to invasive cancer and may also serve as markers for early prostate cancer diagnosis.展开更多
文摘目的研究血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶-26(MMP-26)、基质金属蛋白酶抑制剂-4(TIMP-4)与弥漫大B细胞淋巴瘤(Diffuse large B celllymphoma,DLBCL)病理分期及预后的相关性。方法选取2021年1月1日至2022年4月1日于上海交通大学医学院附属瑞金医院治疗的75例DLBCL患者为研究组,另选取75例淋巴结反应性增生患者作为对照组,观察研究组与对照组及研究组不同分期、不同发病部位血清MMP-9、MMP-26及TIMP-4水平;采用Spearman分析DLBCL患者血清MMP-9、MMP-26与TIMP-4间的相关性;绘制Kaplan-Meier生存曲线,分析MMP-9、MMP-26、TIMP-4水平与DLBCL患者预后的关系。结果研究组血清MMP-9、MMP-26水平均高于对照组,血清TIMP-4水平均低于对照组,差异有统计学意义(P<0.05)。研究组Ⅰ~Ⅱ期患者血清MMP-9、MMP-26水平低于Ⅲ~Ⅳ期患者,血清TIMP-4水平高于Ⅲ~Ⅳ期患者,差异有统计学意义(P<0.05)。研究组不同发病部位患者血清MMP-9、MMP-26、TIMP-4水平比较差异均无统计学意义(P>0.05)。DLBCL患者血清MMP-9、MMP-26水平与TIMP-4水平呈负相关(P<0.05);血清MMP-9水平与MMP-26水平正相关(P<0.05)。MMP-9和MMP-26高表达、TIMP-4低表达组患者累积生存率低于其他组患者,差异具有统计学意义(P<0.05)。结论血清MMP-9、MMP-26及TIMP-4水平与DLBCL病理分期及患者预后密切相关,检测血清MMP-9、MMP-26及TIMP-4水平有助于明确DLBCL病理分期及评价患者预后。
文摘Prostate cancer is one of the leading health threats to man,and like many other cancers,early detection and treatment iscrucial to improving the prognosis of patients.Progression of the disease from noninvasive high-grade prostatic intraepi-thelial neoplasia (HGPIN) to invasive adenocarcinoma is linked to the action of a group of proteolytic enzymes calledmatrix metalloproteinases (MMPs),which digest various components of the extracellular matrix and thus open waysfor tumor metastasis.Previous studies have shown that one MMP,MMP-26,is expressed at a significantly higher levelin human prostate carcinoma than in normal prostate tissues,and that it appears to play an important role in promotinginvasion of prostate cancer cells [1].In this issue of Cell Research,Lee et al.report detailed analyses of the expressionpattern of MMP-26,along with its most potent endogenous inhibitor,TIMP-4 (TIMP stands for tissue inhibitor ofmetal-loproteinases),in a number of prostate cancer samples derived from human patients [2].Interestingly,they found
文摘The identification of novel biomarkers for early prostate cancer diagnosis is highly important because early detection and treatment are critical for the medical management of patients. Disruption in the continuity of both the basal cell layer and basement membrane is essential for the progression of high-grade prostatic intraepithelial neoplasia （HGPIN） to invasive adenocarcinoma in human prostate. The molecules involved in the conversion to an invasive phenotype are the subject of intense scrutiny. We have previously reported that matrix metalloproteinase-26 （MMP-26） promotes the invasion of human prostate cancer cells via the cleavage of basement membrane proteins and by activating the zymogen form of MMP-9. Furthermore, we have found that tissue inhibitor of metalloproteinases-4 （TIMP-4） is the most potent endogenous inhibitor of MMP-26. Here we demonstrate higher （p〈0.0001） MMP-26 and TIMP-4 expression in HGPIN and cancer, compared to non-neoplastic acini. Their expression levels are highest in HGPIN, but decline in invasive cancer （p〈0.001 for each） in the same tissues. Immunohistochemical staining of serial prostate cancer tissue sections suggests colocalization of MMP-26 and TIMP-4. The present study indicates that MMP-26 and TIMP-4 may play an integral role during the conversion of HGPIN to invasive cancer and may also serve as markers for early prostate cancer diagnosis.
